Zentalis Pharmaceuticals, Inc. - 8-K Filing
Zentalis Pharmaceuticals announced that data from Part 1 of its Phase 1b MUIR trial on azenosertib combined with paclitaxel for platinum-resistant ovarian cancer will be presented at the 2026 ASCO Annual Meeting. The clinical activity observed in an all-comer patient population included an overall response rate (ORR) of 39.1%, median progression-free survival (PFS) of 7.3 months, and a manageable safety profile with low rates of high-grade adverse events. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ZNTL